More on the TMC435 PILLAR study (from the PR in #msg-56129587):
Small and transient bilirubin elevations (direct and indirect) were seen in the TMC435 150mg dose groups.
This is essentially the same language as in prior press releases; we’ll presumably have to wait for the actual AASLD presentation to know if there’s a safety problem here.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”